Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

BRONTE, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.121
EU - Europa 4.245
AS - Asia 3.681
SA - Sud America 556
AF - Africa 98
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 8
Totale 18.717
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.023
SG - Singapore 1.437
RU - Federazione Russa 1.107
CN - Cina 971
IT - Italia 736
FI - Finlandia 658
DE - Germania 444
BR - Brasile 423
HK - Hong Kong 332
VN - Vietnam 292
UA - Ucraina 213
PL - Polonia 200
GB - Regno Unito 190
IE - Irlanda 183
FR - Francia 161
JP - Giappone 126
SE - Svezia 122
KR - Corea 111
IN - India 104
CA - Canada 59
RO - Romania 56
BD - Bangladesh 55
BE - Belgio 47
AR - Argentina 46
TR - Turchia 44
IQ - Iraq 42
NL - Olanda 28
CI - Costa d'Avorio 27
ES - Italia 22
VE - Venezuela 22
MX - Messico 21
UZ - Uzbekistan 21
AT - Austria 20
EC - Ecuador 18
MA - Marocco 17
ZA - Sudafrica 17
IR - Iran 16
MY - Malesia 15
CO - Colombia 14
PH - Filippine 14
CH - Svizzera 13
PK - Pakistan 11
CL - Cile 10
ID - Indonesia 10
LB - Libano 10
SA - Arabia Saudita 10
DZ - Algeria 8
NP - Nepal 8
UY - Uruguay 8
KE - Kenya 7
KZ - Kazakistan 7
PY - Paraguay 7
AU - Australia 6
CZ - Repubblica Ceca 6
EG - Egitto 6
IL - Israele 6
PE - Perù 6
EU - Europa 5
JO - Giordania 5
LU - Lussemburgo 5
PS - Palestinian Territory 5
TN - Tunisia 5
AL - Albania 4
AZ - Azerbaigian 4
BY - Bielorussia 4
HU - Ungheria 4
JM - Giamaica 4
LT - Lituania 4
TT - Trinidad e Tobago 4
TW - Taiwan 4
AE - Emirati Arabi Uniti 3
ET - Etiopia 3
GA - Gabon 3
KG - Kirghizistan 3
PA - Panama 3
QA - Qatar 3
BG - Bulgaria 2
BH - Bahrain 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
EE - Estonia 2
GE - Georgia 2
GR - Grecia 2
LV - Lettonia 2
NO - Norvegia 2
RS - Serbia 2
SI - Slovenia 2
SN - Senegal 2
SY - Repubblica araba siriana 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AO - Angola 1
BN - Brunei Darussalam 1
BW - Botswana 1
CR - Costa Rica 1
CU - Cuba 1
CY - Cipro 1
DK - Danimarca 1
GD - Grenada 1
Totale 18.706
Salva come PNG Salva come JPEG
Città #
Fairfield 1.439
Ashburn 1.261
Singapore 937
Woodbridge 765
Wilmington 575
Seattle 573
Chandler 572
Houston 545
Cambridge 526
Ann Arbor 494
Hong Kong 322
San Jose 314
Moscow 201
Palermo 184
Dublin 175
Zgierz 170
Beijing 166
Council Bluffs 166
Medford 142
Des Moines 130
Santa Clara 119
Altamura 118
Los Angeles 118
Tokyo 114
Nanjing 112
Helsinki 109
Jacksonville 108
Ho Chi Minh City 97
New York 93
Princeton 90
The Dalles 84
Lawrence 80
Lauterbourg 79
San Diego 73
Dallas 72
Frankfurt am Main 72
Hanoi 67
Boardman 53
Hefei 52
Dearborn 50
Phoenix 50
Brussels 46
Chicago 44
London 44
São Paulo 42
Tulsa 42
Ludwigshafen am Rhein 39
Changsha 37
Orem 37
Buffalo 35
Seoul 35
Nanchang 33
Shenyang 33
Jiaxing 31
Tianjin 31
Hebei 29
Abidjan 27
Bremen 27
Izmir 26
Munich 25
Panama City 25
Chennai 24
Denver 23
Jinan 23
Nuremberg 23
Warsaw 23
Da Nang 22
Kitzingen 22
Guangzhou 21
Kumar 21
Milan 20
Saint Petersburg 20
Seongnam 20
Baghdad 19
Zhengzhou 18
Montreal 17
Belo Horizonte 16
Ningbo 16
Rome 16
San Paolo di Civitate 15
Washington 15
Hangzhou 14
Toronto 14
Amsterdam 13
Brooklyn 13
Turku 13
Venice 13
Atlanta 12
Haiphong 12
Poplar 12
Tashkent 12
Columbus 11
Mumbai 11
Stockholm 11
Berlin 10
Rio de Janeiro 10
Shanghai 10
Ankara 9
Johannesburg 9
Pune 9
Totale 12.767
Salva come PNG Salva come JPEG
Nome #
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus 349
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis 341
Dietary restriction: could it be considered as speed bump on tumor progression road? 322
Stabilizing versus destabilizing the microtubules: A double-edge sword for an effective cancer treatment option? 310
Analysis of Germline Gene Copy Number Variants of Patients with Sporadic Pancreatic Adenocarcinoma Reveals Specific Variations 305
Anti-endothelin drugs in solid tumors 296
EGF Induces STAT3-Dependent VEGF Expression in HT-29 colon cancer cells 289
Analysis of germline gene copy number variants of patients with sporadic pancreatic adenocarcinoma reveals specific variations 286
A headlight on liquid biopsies: a challenging tool for breast cancer management 280
I tumori della mammella e/o dell’ovaio di tipo eredofamiliare: strategie di prevenzione nelle donne ad alto rischio 270
BRCA1 and BRCA2 germline mutations in sicilian breast and/or ovarian cancer families and their association with familial profiles 267
BRCA1 and BRCA2 variants of uncertain clinical significance and their implications for genetic counseling 263
How Much of Familial Breast Cancer Risk is Currently Explained by the Known Genes? 263
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects 263
Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: there is a sense in antisense? 262
HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma 257
The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies 253
What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment 253
Antiemetic prophylaxis containing Palonosetron (P) alone or in combination with Aprepitant (A) in the treatment of advanced soft tissue sarcoma (STS) patients with epirubicin and ifosfamide 252
Targeted Therapies in Hepatocellular Carcinoma 252
Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors 252
Nintedanib in NSCLC: Evidence to date and place in therapy 252
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS? 249
HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions 247
Monoclonal antibodies in gastrointestinal cancers 243
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis 243
Farletuzumab for NSCLC: Exploiting a well-known metabolic pathway for a new therapeutic strategy 241
EGFR genomic alterations in cancer: prognostic and predictive values 237
MicroRNAs in colorectal cancer stem cells: new regulators of cancer stemness? 236
Cancer and the microbiome: Potential applications as new tumor biomarker 235
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? 234
MicroRNAs in Colorectal Cancer Drug Resistance: Shooters become Targets 233
Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma 233
Hypoxia and Human Genome Stability: Downregulation of BRCA2 Expression in Breast Cancer Cell Lines 232
Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer? 230
Downregulated expression of Cdc25A gene in MCF-7 breast cancer cell 229
Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors 226
BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer 226
Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward 226
A Phase II Trial of Fixed-Dose Rate Gemcitabine plus Capecitabine in Metastatic/Advanced Biliary Tract Cancer Patients 225
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis 225
Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy 225
Multisciplinary management of patients with liver metastasis from colorectal cancer 222
The role of targeted therapy for gastrointestinal tumors 222
HER2-positive male breast cancer: An update 218
Sex steroids, carcinogenesis, and cancer progression 218
Circulating miR-22, miR-24 and miR-34a as Novel Predictive Biomarkers to Pemetrexed-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer 215
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 215
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma 207
Dilemma in metastatic colorectal cancer: VEGF versus EGRF targeting 205
Well-being among Italian medical oncologists: An exploratory study 203
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis 202
Monoclonal antibodies for the treatment of non-haematological tumours: Update of an expanding scenario 199
Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: A literature-based meta-analysis 198
Bortezomib: a new pro-apoptotic agent in cancer treatment. 197
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 195
Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy? 192
Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor 192
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? 189
A literature-based meta-analysis of the comparison between Gemcitabine-based combination and monochemotherapy for the treatment of advanced non-small cell lung cancer in elderly patients 188
The molecular changes driving the carcinogenesis in Barrett's esophagus: Which came first, the chicken or the egg? 186
Predicting efficacy and toxicity in the era of targeted therapy: focus on anti-EGFR and anti-VEGF molecules 185
Plasma levels of angiogenetic markers in men candidate to prostate biopsy 181
Management of Toxicity Induced by Anti-EGFR Therapy in Metastatic Colorectal Cancer 177
A non common BRAF mutation c1799-1801 delTGA identified in sporadic colon rectal cancer of sicilian patients 176
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard? 176
Studio pilota sul valore predittivo dei livelli plasmatici di 9 fattori angiogenetici nella selezione di pazienti candidati alla biopsia prostatica 175
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients 174
Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma 172
Into the wild of long non-coding RNA in gastrointestinal stromal tumors (GISTs) to explore new prognostic/predictive biomarkers 171
Comparison between gemcitabine-based combination (G) and single-agent chemotherapy (S) for elderly patients (EP) with advanced non-small cell lung cancer (NSCLC): A literature-based meta-analysis. 170
Corrigendum: Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? 168
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? 162
ALK and crizotinib: After the honeymoon...what else? Resistance mechanisms and new therapies to overcome it 160
Impact of the new 5-HT3 receptor antagonist palonosetron (P) in chemotherapy-induced nausea and vomiting (CINV) control in elderly advanced breast cancer (EABC) patients: Comparison with the classic antiemetic agent ondansetron (O). 160
Low dose splenic irradiation in myelofibrosis: outcomes and toxicity of three radiation schedule 157
Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls? 153
How to find the Ariadne's thread in the labyrinth of salvage treatment options for metastatic colorectal cancer? 152
An all-oral combination regimen of vinorelbine and capecitabine for elderly patients with metastatic breast cancer 151
Serum levels of angiogenetic cancer biomarkers in men undergoing prostate biopsy. Preliminary data 148
The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target? 147
Apoptosis in Thyroid Autoimunity. 146
Capecitabine (XEL) + Oxaliplatin (OX) in elderly people (EP) with Colorectal Cancer (CRC): Comparison of safety (S) and feasibility (F) of two different schedules. Preliminary findings 144
The long and winding road to useful predictive factors for anti-egfr therapy in metastatic colorectal carcinoma: The KRAS/BRAF pathway 144
Efficacy of weekly low-dose chemotherapy in elderly women with advanced ovarian cancer: is there an antiangiogenic effect? 142
Germline copy number variation in the YTHDC2 gene: does it have a role in finding a novel potential molecular target involved in pancreatic adenocarcinoma susceptibility? 139
VIPoma and PPoma 139
Ramucirumab and its use in gastric cancer treatment 138
Safety and efficacy of two different schedules of capecitabine combined with oxaliplatin in the treatment of colon cancer in the elderly 103
RECHALLENGE WITH ANTI-EGFR MONOCLONAL ANTIBODIES IN PRETREATED METASTATIC COLORECTAL CANCER PATIENTS: BEYOND THE LIMITS OF ACQUIRED RESISTANCE 98
Totale 19.183
Salva come PNG Salva come JPEG
Categoria #
all - tutte 61.997
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 61.997
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021331 0 0 0 0 0 0 0 0 0 0 159 172
2021/20221.317 58 284 72 64 63 50 72 86 117 153 102 196
2022/20231.649 176 354 31 197 183 230 109 110 154 6 67 32
2023/2024666 29 87 51 51 47 132 64 86 7 10 9 93
2024/20251.855 25 151 184 136 60 66 111 190 99 190 250 393
2025/20265.937 523 200 329 474 626 916 810 733 449 694 183 0
Totale 19.183